Finance

Lists
BLRX:NASDAQ
BioLine RX Ltd - ADR
$2.57
+0.76%
(+0.020) 1D
Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLRX...
Open
$2.53
High
$2.63
Low
$2.52
Mkt. cap
12.63M
Avg. vol.
20.25K
Volume
0.00
52-wk high
$4.56
52-wk low
$2.16
EPS
-$0.49
Beta
1.56
Shares outstanding
4.85M
No. of employees
22
Open
$2.53
High
$2.63
Low
$2.52
Mkt. cap
12.63M
Avg. vol.
20.25K
Volume
0.00
52-wk high
$4.56
52-wk low
$2.16
EPS
-$0.49
Beta
1.56
Shares outstanding
4.85M
No. of employees
22
News stories
From web sources and news partners
Profile
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Wikipedia
About BioLine RX Ltd - ADR
CEOPhilip A. Serlin
Employees22
Founded2003
Headquarters-
SectorBiotechnology
Websitebiolinerx.com
Analyst ratings
Based on 1 analyst giving stock ratings to BLRX in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for BLRX in the last 3 months
Highest
Current $2.57
$26.00 (+911.87%)
Average
$26.00 (+911.87%)
Lowest
$26.00 (+911.87%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$26.00
+911.9%
08/31/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$12.00
+367%
06/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
427.00K
194.00K
477.00K
294.00K
Cost of goods sold
84.00K
40.00K
95.00K
59.00K
Cost of revenue
84.00K
40.00K
95.00K
59.00K
Research and development expenses
1.72M
2.42M
2.53M
2.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
831.00K
1.12M
858.00K
865.00K
Operating expense
2.55M
3.54M
3.39M
3.81M
Total operating expenses
2.63M
3.58M
3.48M
3.87M
Operating income
-2.21M
-3.39M
-3.00M
-3.57M
Other non operating income
1.16M
1.10M
458.00K
-690.00K
EBT including unusual items
-977.00K
-2.24M
-2.59M
-4.34M
EBT excluding unusual items
-977.00K
-2.24M
-2.59M
-4.34M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-977.00K
-1.38M
-1.60M
-3.03M
Net profit margin
-228.81%
-713.92%
-335.64%
-1,029.25%
Earnings per share
-
-
-
-
Interest and investment income
377.00K
-
208.00K
132.00K
Interest expense
-304.00K
-288.00K
-250.00K
-208.00K
Net interest expenses
73.00K
-288.00K
-42.00K
-76.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.09M
-3.33M
-2.92M
-3.50M
Gain or loss from assets sale
-
25.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps